| Title | Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus |
| Authors | Niu, Siwen Si, Longlong Liu, Dong Zhou, Andrew Zhang, Ziwei Shao, Zongze Wang, Shaomeng Zhang, Lihe Zhou, Demin Lin, Wenhan |
| Affiliation | Peking Univ, State Key Lab Nat & Biomimet Drugs, 38 Xueyuan Rd, Beijing 100191, Peoples R China. SOA, Inst Oceanog 3, Key Lab Marine Biogenet Resources, Xiamen 361005, Peoples R China. Univ Michigan, Ctr Comprehens Canc, 7500 East Med Ctr Dr, Ann Arbor, MI 48109 USA. |
| Keywords | Marine-derived fungus Spiromastix sp. Spiromastilactones Influenza virus Antiviral effect Mechanistic investigation ISOLATED WORLDWIDE RECEPTOR-BINDING HEMAGGLUTININ REPLICATION RESISTANCE MECHANISM INFECTION DESIGN |
| Issue Date | 2016 |
| Publisher | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY |
| Citation | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.2016,108,229-244. |
| Abstract | A new class of phenolic lactones with trivial names of spiromastilactones A-M (1-13) was isolated from a deep-sea derived Spiromastix sp. fungus. Their structures featured by various chlorination at aromatic rings were determined on the basis of extensive spectroscopic analyses. An antiviral assay revealed that most of the tested compounds exert inhibitory activity against WSN influenza virus with low cytotoxicity, while the structure activity relationships were discussed. Spiromastilactone D (4), a 5'-chloro-2'-methoxy substituted analogue, displayed the most potent to inhibit a panel of influenza A and B viruses in addition to drug-resistant clinical isolates. Mechanistic investigation resulted in that compound 4 bonded to hemagglutinin protein (HA), potentially at the spherical head, and disrupted the HA-sialic acid receptor interaction, that is essential for the attachment and entry of all influenza viruses. In addition, compound 4 also showed inhibitory effect toward viral genome replication via targeting viral RNP complex. The synergistic effects of 4 on both viral entry and replication assumed it to be a promising lead for the development of a new influenza inhibitor. (C) 2015 Elsevier Masson SAS. All rights reserved. |
| URI | http://hdl.handle.net/20.500.11897/435790 |
| ISSN | 0223-5234 |
| DOI | 10.1016/j.ejmech.2015.09.037 |
| Indexed | SCI(E) PubMed |
| Appears in Collections: | 天然药物与仿生药物国家重点实验室 |
